Health Catalyst, Inc. (NASDAQ:HCAT) Stock Position Increased by Daventry Group LP

Daventry Group LP lifted its position in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 3.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,509,480 shares of the company's stock after purchasing an additional 91,878 shares during the quarter. Health Catalyst comprises 6.8% of Daventry Group LP's holdings, making the stock its 8th largest position. Daventry Group LP owned approximately 4.12% of Health Catalyst worth $17,742,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. First Light Asset Management LLC boosted its stake in shares of Health Catalyst by 22.0% in the fourth quarter. First Light Asset Management LLC now owns 5,241,121 shares of the company's stock worth $37,055,000 after buying an additional 944,631 shares during the last quarter. Impax Asset Management Group plc lifted its holdings in Health Catalyst by 7.7% in the fourth quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company's stock valued at $19,442,000 after acquiring an additional 195,525 shares during the period. Alyeska Investment Group L.P. boosted its position in Health Catalyst by 74.4% in the 4th quarter. Alyeska Investment Group L.P. now owns 2,019,380 shares of the company's stock worth $14,277,000 after purchasing an additional 861,150 shares in the last quarter. Kennedy Capital Management LLC grew its stake in shares of Health Catalyst by 42.7% during the 4th quarter. Kennedy Capital Management LLC now owns 1,891,000 shares of the company's stock worth $13,369,000 after purchasing an additional 565,445 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Health Catalyst by 17.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,591,565 shares of the company's stock valued at $11,252,000 after purchasing an additional 235,686 shares in the last quarter. Institutional investors and hedge funds own 85.00% of the company's stock.

Insider Buying and Selling

In other news, insider Linda Llewelyn sold 6,441 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $5.43, for a total transaction of $34,974.63. Following the completion of the sale, the insider now owns 85,819 shares in the company, valued at $465,997.17. This trade represents a 6.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Daniel Lesueur sold 16,902 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $4.52, for a total value of $76,397.04. Following the completion of the transaction, the chief operating officer now owns 216,250 shares in the company, valued at $977,450. This represents a 7.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 42,379 shares of company stock worth $195,902. 2.50% of the stock is owned by corporate insiders.

Health Catalyst Trading Up 0.1 %

HCAT opened at $4.08 on Wednesday. The firm has a market capitalization of $286.11 million, a price-to-earnings ratio of -3.02 and a beta of 1.56. The company's 50 day simple moving average is $4.16 and its two-hundred day simple moving average is $6.01. Health Catalyst, Inc. has a 1-year low of $3.56 and a 1-year high of $9.24. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on HCAT shares. Wells Fargo & Company lowered their price target on Health Catalyst from $13.00 to $10.00 and set an "overweight" rating on the stock in a research report on Tuesday, January 21st. Stifel Nicolaus decreased their target price on Health Catalyst from $10.00 to $5.00 and set a "hold" rating on the stock in a research report on Thursday, February 27th. KeyCorp cut their price target on shares of Health Catalyst from $7.00 to $5.00 and set an "overweight" rating for the company in a report on Wednesday, April 16th. Royal Bank of Canada decreased their price objective on shares of Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating on the stock in a report on Thursday, February 27th. Finally, Piper Sandler cut their target price on shares of Health Catalyst from $12.00 to $8.00 and set an "overweight" rating for the company in a research note on Tuesday, February 11th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $8.05.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.